Consensus Edwards Lifesciences Corporation

Stocks

EW

US28176E1082

Advanced Medical Equipment & Technology

Market Closed - NYSE 16:00:03 2026-08-31 EDT			5-day change	1st Jan Change
90.75 ^USD	+0.60%		+0.28%	+6.45%

08-27	Edwards Lifesciences Insider Sold Shares Worth $2,894,440, According to a Recent SEC Filing	MT
08-21	Argus Adjusts Price Target on Edwards Lifesciences to $115 From $105, Maintains Buy Rating	MT

Evolution of the Average Target: Edwards Lifesciences Corporation

Evolution of the Target Price: Edwards Lifesciences Corporation

Changes in Analyst Recommendations: Edwards Lifesciences Corporation

4f2e2c0eb.SP8o0WHXQBuiFet_15RsCoX130FCRlZ4ZA0vwADJX58.MrdbhQKAdl_4eYoKo9EDScShqSkMDRQSVzQWiFX4KfIKvhyTM79yeu0gmA~fd77cdb394cb098b8915f6b39d01aa21

Analysts' recommendations: Edwards Lifesciences Corporation

08-21	Argus Adjusts Price Target on Edwards Lifesciences to $115 From $105, Maintains Buy Rating	MT
07-28	UBS Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $110 From $90	MT
07-27	Rothschild & Co Redburn Adjusts Edwards Lifesciences Price Target to $102 From $99, Maintains Buy Rating	MT
07-24	Edwards Lifesciences Seen Building on Catalyst Pipeline, RBC Says	MT
07-24	Deutsche Bank Adjusts Edwards Lifesciences Price Target to $103 From $100, Maintains Buy Rating	MT
07-24	Raymond James Adjusts Price Target on Edwards Lifesciences to $103 From $100, Maintains Outperform Rating	MT
07-24	Piper Sandler Adjusts Price Target on Edwards Lifesciences to $101 From $100, Maintains Overweight Rating	MT
07-24	Jefferies Adjusts Price Target on Edwards Lifesciences to $105 From $102, Maintains Buy Rating	MT
07-24	Bernstein Adjusts Price Target on Edwards Lifesciences to $99 From $96, Maintains Market Perform Rating	MT
07-24	Leerink Partners Upgrades Edwards Lifesciences to Outperform From Market Perform, Adjusts PT to $101 From $87	MT
07-16	Truist Adjusts Price Target on Edwards Lifesciences to $95 From $90, Maintains Hold Rating	MT
07-15	Mizuho Adjusts Price Target on Edwards Lifesciences to $105 From $100, Maintains Outperform Rating	MT
07-14	Baird Adjusts Price Target on Edwards Lifesciences to $94 From $87, Maintains Neutral Rating	MT
07-14	Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $102 From $98, Maintains Buy Rating	MT
07-13	RBC Raises Price Target on Edwards Lifesciences to $110 From $100, Keeps Outperform Rating	MT
07-08	Citigroup Adjusts Edwards Lifesciences Price Target to $110 From $101	MT
07-06	Evercore ISI Adjusts Price Target on Edwards Lifesciences to $100 From $93	MT
06-30	BTIG Adjusts Price Target on Edwards Lifesciences to $110 From $100, Maintains Buy Rating	MT
06-29	Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says	MT
06-16	Edwards Lifesciences Seen Benefiting From CMS Transcatheter Aortic Valve Replacement Rule, RBC Says	MT
06-11	Edwards Lifesciences Set to Benefit from TAVR Coverage Update, RBC Says	MT
06-02	TD Cowen Adjusts Price Target on Edwards Lifesciences to $104 From $97, Maintains Buy Rating	MT
04-28	Rothschild & Co Redburn Adjusts Price Target on Edwards Lifesciences to $99 From $94, Maintains Buy Rating	MT
04-24	Mizuho Securities Adjusts Edwards Lifesciences Price Target to $100 From $95, Maintains Outperform Rating	MT
04-24	Truist Securities Adjusts Price Target on Edwards Lifesciences to $90 From $89, Maintains Hold Rating	MT

More recommendations

Other Advanced Medical Equipment & Technology

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EDWARDS LIFESCIENCES CORPORATION					+11.92%
	THERMO FISHER SCIENTIFIC, INC.					+1.49%
	DANAHER CORPORATION					+5.5%
	INTUITIVE SURGICAL, INC.					+28.29%
	BOSTON SCIENTIFIC CORPORATION					+33.84%
	SIEMENS HEALTHINEERS AG					+14.23%
	AGILENT TECHNOLOGIES, INC.					+13.36%
	WATERS CORPORATION					+5.98%
	RESMED, INC.					+2.15%
	ILLUMINA, INC.					-7.74%
	Average					+10.90%
	Weighted average by Cap.					+11.00%